Gut decisions in CAR T cell therapy dlvr.it/T0GR04

CAR T cell therapy for multiple myeloma dlvr.it/T0GR08

Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities dlvr.it/T0GR0B

The impact of COVID-19 on cancer patients dlvr.it/T0GR73

Current advances in bacteria-based cancer immunotherapy dlvr.it/T0Gy03

The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation dlvr.it/T0H4Gy

Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia dlvr.it/T0H4JQ

GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma dlvr.it/T0HZgQ

Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment dlvr.it/T0HmXV

Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma dlvr.it/T0JNNz

Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma dlvr.it/T0JNYN

Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing dlvr.it/T0Jyr6

Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing dlvr.it/T0K8rg

Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms dlvr.it/T0Kf94

Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! dlvr.it/T0LNkf

A bibliometric and knowledge-map study of CAR-T cell-related cytokine release syndrome (CRS) from 2012 to 2023 dlvr.it/T0LNnm

Oncolytic viruses in lung cancer treatment: a review article dlvr.it/T0LP6j

A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer dlvr.it/T0LP7h

Pediatric Chimeric Antigen Receptor (CAR) T-Cell Therapy (PDQ®): Health Professional Version dlvr.it/T0MdV3

Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer dlvr.it/T0MddF